Keywords: pfizer, 3rd-qtr, earnings, double, share, price, falls
Pfizer 3rd-qtr earnings double, but share price falls on projected flat sales
Article | 30 October 2006
Global pharmaceuticals giant Pfizer has posted third-quarter 2006 results showing that turnover grew 9% to $12.28 billion and diluted earnings per share leapt 109% ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
